このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Quanterix 将来の成長

Future 基準チェック /16

Quanterixは、25.2%と15.3%でそれぞれ年率25.2%で利益と収益が成長すると予測される一方、EPSはgrowで26.4%年率。

主要情報

25.2%

収益成長率

26.4%

EPS成長率

Life Sciences 収益成長	16.2%
収益成長率	15.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 Jun 2024

今後の成長に関する最新情報

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Mar 03

Recent updates

Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump

Jun 27

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Apr 14

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Apr 05

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Mar 03

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Oct 12

業績と収益の成長予測

NasdaqGM:QTRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	204	-21	-32	-4	3
12/31/2025	169	-33	-38	-8	5
12/31/2024	142	-37	-41	-14	5
3/31/2024	126	-36	-34	-30	N/A
12/31/2023	122	-32	-23	-19	N/A
9/30/2023	117	-39	-20	-17	N/A
6/30/2023	112	-66	-34	-28	N/A
3/31/2023	104	-85	-47	-36	N/A
12/31/2022	106	-97	-60	-48	N/A
9/30/2022	110	-98	-67	-54	N/A
6/30/2022	111	-79	-66	-54	N/A
3/31/2022	113	-66	-70	-56	N/A
12/31/2021	111	-58	-62	-48	N/A
9/30/2021	106	-47	-46	-33	N/A
6/30/2021	110	-30	-37	-27	N/A
3/31/2021	98	-30	-28	-24	N/A
12/31/2020	86	-32	-27	-23	N/A
9/30/2020	76	-33	-35	-33	N/A
6/30/2020	60	-45	-36	-34	N/A
3/31/2020	60	-43	-39	-34	N/A
12/31/2019	57	-41	-37	-26	N/A
9/30/2019	52	-39	-40	-30	N/A
6/30/2019	47	-37	-38	-28	N/A
3/31/2019	42	-34	-31	-24	N/A
12/31/2018	38	-32	-30	-29	N/A
9/30/2018	33	-30	-27	-25	N/A
6/30/2018	28	-30	-27	-26	N/A
3/31/2018	25	-31	-30	-28	N/A
12/31/2017	23	-31	N/A	-22	N/A
9/30/2017	23	-31	N/A	-22	N/A
6/30/2017	21	-30	N/A	-20	N/A
3/31/2017	19	-30	N/A	-19	N/A
12/31/2016	18	-28	N/A	-18	N/A
12/31/2015	12	-20	N/A	-13	N/A

アナリストによる今後の成長予測

収入対貯蓄率: QTRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: QTRX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: QTRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: QTRXの収益 ( 15.3% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: QTRXの収益 ( 15.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: QTRXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Quanterix 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Quanterix Corporation Provides Earnings Guidance for the Full-Year 2024

Price target decreased by 9.7% to US$29.80

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Quanterix Corporation Provides Earnings Guidance for the Year 2024

Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023

Price target increased by 11% to US$33.25

Recent updates

Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation Provides Earnings Guidance for the Full-Year 2024

Quanterix Corporation to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 9.7% to US$29.80

New minor risk - Shareholder dilution

Quanterix Corporation, Annual General Meeting, Jun 03, 2024

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS misses analyst expectations

Quanterix Corporation Provides Earnings Guidance for the Year 2024

Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023

Quanterix Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 11% to US$33.25

New minor risk - Shareholder dilution

Quanterix Corporation Revises Earnings Guidance for the 2023

Quanterix Corporation Revises Earnings Guidance for the 2023

New major risk - Revenue and earnings growth

Quanterix Corporation to Report Q3, 2023 Results on Nov 06, 2023

Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Price target increased by 9.7% to US$31.00

Director recently bought US$502k worth of stock

High number of new directors

Quanterix Corporation Appoints William (Bill) P. Donnelly to its Board of Directors

Consensus estimates of losses per share improve by 20%

Quanterix Corporation Announces Michael Doyle Cease Serving as Treasurer, Effective August 21, 2023

Quanterix Corporation Provides Earnings Guidance for the Full-Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation to Report Q2, 2023 Results on Aug 08, 2023

Quanterix Corporation Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer's Disease in Patients

We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$15.25

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Brian Blaser to Board of Directors

Quanterix Corporation Simoa Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease Conference

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Quanterix Corporation Reports Goodwill Impairment for the Third Quarter Ended September 30, 2022

Quanterix Corporation to Report Q3, 2022 Results on Nov 08, 2022

Quanterix Corporation: Selling For Less Than Cash Value

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Daniel Pikora as Chief Operating Officer

Quanterix stock gains after insider buys reported by CEO and CFO

Consensus forecasts updated

Independent Director recently bought US$2.0m worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Quanterix Corporation Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors

Quanterix Corporation to Report Q2, 2022 Results on Aug 08, 2022

Price target decreased to US$34.50

Quanterix Corporation Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S

Quanterix Corporation Announces Resignation of John Fry as General Counsel and Secretary, Effective August 12, 2022

President recently sold US$85k worth of stock

Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

Quanterix Corporation Announces Resignation of Dawn Mattoon as Senior Vice President, Diagnostics, Effective July 10, 2022

Consensus forecasts updated

Price target decreased to US$45.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation to Report Q1, 2022 Results on May 10, 2022

Quanterix Corporation, Annual General Meeting, Jun 23, 2022

Quanterix Corporation Grants Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis

Quanterix Corporation announced that it has received funding from Alzheimers Drug Discovery Foundation

We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely